LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Reports Second Quarter 2024 Financial Results and Business Update
August 20, 2024 07:30 ET
|
LAVA Therapeutics N.V.
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for...
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024 07:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Announces Annual Meeting of Shareholders
June 10, 2024 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on...
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from...
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024 16:05 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on...
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for...
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
March 05, 2024 07:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
January 25, 2024 07:00 ET
|
LAVA Therapeutics N.V.
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the...